PapersFlow Research Brief
Methemoglobinemia and Tumor Lysis Syndrome
Research Guide
What is Methemoglobinemia and Tumor Lysis Syndrome?
Methemoglobinemia and Tumor Lysis Syndrome refers to the cluster of medical literature addressing methemoglobinemia, a condition impairing oxygen transport due to oxidized hemoglobin, alongside tumor lysis syndrome (TLS), a life-threatening oncologic emergency from rapid tumor cell breakdown causing metabolic disturbances like hyperuricemia and acute kidney injury, often managed with agents such as rasburicase and dapsone in chemotherapy patients.
This field encompasses 12,958 papers on the management, treatment, and complications of TLS, including risk evaluation, prophylaxis, and therapies like rasburicase for hematologic malignancies in pediatric and adult patients. Related conditions such as methemoglobinemia and hyperuricemia are examined, particularly in contexts of chemotherapy-induced emergencies. Growth rate over the past 5 years is not available from the data.
Topic Hierarchy
Research Sub-Topics
Tumor Lysis Syndrome Risk Stratification
Researchers develop and validate scoring systems like Cairo-Bishop criteria and machine learning models to predict TLS risk in hematologic malignancy patients pre-chemotherapy. Studies incorporate tumor burden, laboratory markers, and patient factors.
Rasburicase in Tumor Lysis Syndrome Management
Clinical trials and pharmacodynamic studies evaluate recombinant urate oxidase efficacy, dosing, and safety in high-risk TLS patients, including cost-effectiveness and G6PD screening protocols. Pediatric and adult outcomes are compared.
Methemoglobinemia Management in Oncology
This sub-topic examines dapsone-induced methemoglobinemia in TLS prophylaxis, methylene blue reversal kinetics, and alternative therapies in chemotherapy patients with G6PD deficiency. Case series inform guidelines.
Hyperuricemia Prophylaxis in Chemotherapy
Investigations compare allopurinol, rasburicase, and combination regimens for preventing chemotherapy-induced hyperuricemia and acute kidney injury in leukemias and lymphomas. Biomarkers and renal outcomes are tracked.
Pediatric Tumor Lysis Syndrome
Pediatric studies focus on TLS incidence, rasburicase pharmacokinetics, and supportive care protocols in acute lymphoblastic leukemia and Burkitt lymphoma treatments. Age-specific risk factors and long-term sequelae are analyzed.
Why It Matters
Tumor lysis syndrome represents the most common disease-related emergency in children and adults with hematologic cancers, necessitating strategies for risk assessment, prophylaxis, and therapy as outlined by Howard et al. (2011) in "The Tumor Lysis Syndrome." Rasburicase, a urate oxidase, addresses hyperuricemia in TLS, while methemoglobinemia arises as a potential complication from drugs like dapsone used in prophylaxis. Cairo and Bishop (2004) in "Tumour lysis syndrome: new therapeutic strategies and classification" detail metabolic derangements from tumor breakdown, impacting acute kidney injury rates of 2%-12% in high-dose methotrexate cases per Howard et al. (2016) in "Preventing and Managing Toxicities of High-Dose Methotrexate." These insights guide clinical management in pediatric oncology to avert fatalities.
Reading Guide
Where to Start
"The Tumor Lysis Syndrome" by Howard et al. (2011) is the recommended starting paper, as it provides a concise summary of risk assessment, prophylaxis, and therapy for TLS, the core emergency in this cluster.
Key Papers Explained
Cairo and Bishop (2004) in "Tumour lysis syndrome: new therapeutic strategies and classification" establishes TLS classification and strategies, which Howard et al. (2011) in "The Tumor Lysis Syndrome" builds upon with updated risk and prophylaxis summaries for hematologic cancers. Wright et al. (1999) in "Methemoglobinemia: Etiology, Pharmacology, and Clinical Management" details methemoglobinemia management relevant to TLS drug complications like dapsone. Howard et al. (2016) in "Preventing and Managing Toxicities of High-Dose Methotrexate" connects TLS to chemotherapy toxicities, including AKI risks of 2%-12%. Cappellini and Fiorelli (2008) in "Glucose-6-phosphate dehydrogenase deficiency" addresses predispositions affecting rasburicase safety.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Frontiers center on TLS prophylaxis in high-risk chemotherapy for hematologic malignancies, with ongoing needs in rasburicase optimization and dapsone-related methemoglobinemia risks, as no recent preprints or news are available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Management of Hyperbilirubinemia in the Newborn Infant 35 or M... | 2004 | PEDIATRICS | 2.8K | ✕ |
| 2 | Glucose-6-phosphate dehydrogenase deficiency | 2008 | The Lancet | 1.5K | ✕ |
| 3 | Tumour lysis syndrome: new therapeutic strategies and classifi... | 2004 | British Journal of Hae... | 1.0K | ✕ |
| 4 | The Tumor Lysis Syndrome | 2011 | New England Journal of... | 951 | ✕ |
| 5 | A Syndrome Produced by Diverse Nocuous Agents | 1998 | Journal of Neuropsychi... | 904 | ✕ |
| 6 | Predictive Ability of a Predischarge Hour-specific Serum Bilir... | 1999 | PEDIATRICS | 876 | ✕ |
| 7 | Workgroup Report: Drinking-Water Nitrate and Health—Recent Fin... | 2005 | Environmental Health P... | 857 | ✓ |
| 8 | Racial variability in the UDP-glucuronosyltransferase 1 ( <i>U... | 1998 | Proceedings of the Nat... | 844 | ✓ |
| 9 | Preventing and Managing Toxicities of High-Dose Methotrexate | 2016 | The Oncologist | 836 | ✓ |
| 10 | Methemoglobinemia: Etiology, Pharmacology, and Clinical Manage... | 1999 | Annals of Emergency Me... | 822 | ✕ |
Frequently Asked Questions
What is tumor lysis syndrome?
Tumor lysis syndrome describes metabolic derangements from rapid tumor cell destruction after cytotoxic therapy, releasing intracellular ions, nucleic acids, proteins, and metabolites. It commonly affects patients with hematologic cancers undergoing chemotherapy. Cairo and Bishop (2004) in "Tumour lysis syndrome: new therapeutic strategies and classification" classify and propose strategies for its management.
How is TLS treated in hematologic malignancies?
Current strategies include risk assessment, prophylaxis, and therapy targeting hyperuricemia with rasburicase. TLS is the most common emergency in children and adults with hematologic cancers. Howard et al. (2011) in "The Tumor Lysis Syndrome" summarize these approaches.
What causes methemoglobinemia?
Methemoglobinemia results from hemoglobin oxidation impairing oxygen delivery, often linked to agents like nitrates in drinking water affecting infants. U.S. guidelines limit nitrate levels to prevent this acute condition. Ward et al. (2005) in "Workgroup Report: Drinking-Water Nitrate and Health—Recent Findings and Research Needs" discuss nitrate accumulation and health risks.
What are the clinical management steps for methemoglobinemia?
Management involves addressing etiology, pharmacology, and supportive care. Wright et al. (1999) in "Methemoglobinemia: Etiology, Pharmacology, and Clinical Management" cover these aspects comprehensively. The condition requires prompt intervention to restore oxygen transport.
How does chemotherapy contribute to TLS?
Chemotherapy initiation causes rapid malignant cell lysis, leading to TLS metabolic disturbances. Prophylaxis with rasburicase prevents hyperuricemia complications. The cluster highlights this in pediatric oncology contexts.
What role does rasburicase play in TLS?
Rasburicase, a urate oxidase, treats hyperuricemia in TLS by breaking down uric acid. It is a key therapeutic in high-risk chemotherapy patients. Keywords from the cluster emphasize its use in oncologic emergencies.
Open Research Questions
- ? How can risk stratification for TLS be improved beyond current models in diverse hematologic malignancy populations?
- ? What are the long-term renal outcomes in TLS patients treated with rasburicase versus alternatives?
- ? Why do certain chemotherapy regimens trigger methemoglobinemia, and how can dapsone-related risks be mitigated?
- ? Which genetic factors, beyond G6PD deficiency, predict severe TLS or methemoglobinemia in pediatric patients?
- ? How does hyperuricemia in TLS interact with acute kidney injury mechanisms during high-dose methotrexate therapy?
Recent Trends
The field maintains 12,958 works without specified 5-year growth data; persistent focus remains on TLS management in chemotherapy, rasburicase for hyperuricemia, and methemoglobinemia from agents like dapsone, per top-cited papers such as Howard et al.
2011No recent preprints or news coverage indicate stable research emphasis on established strategies.
Research Methemoglobinemia and Tumor Lysis Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Methemoglobinemia and Tumor Lysis Syndrome with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers